Strand Life Sciences' CancerSpot Study Reveals DNA Insights for Early Cancer Detection
A groundbreaking study published in PNAS highlights how increased DNA in blood can enhance cancer detection accuracy.
The CancerSpot study analyzed blood samples from 1,480 subjects across 43 hospitals in India.
Higher levels of circulating DNA correlate with improved sensitivity in detecting cancer signals.
The CancerSpot technology shows a low false positive rate of 1.4% while detecting 72% of cancer cases.
Strand Life Sciences has achieved a significant milestone with the publication of its CancerSpot study in the Proceedings of the National Academy of Sciences (PNAS). This research, which spanned four years and involved 43 hospitals across India, focuses on the detection of cancer-associated signals in blood samples, providing new insights into non-invasive early cancer detection and the interaction between tumors and the immune system.
The study examined blood samples from 1,480 individuals, including newly diagnosed cancer patients and healthy controls. It was found that while tumor cells release short DNA fragments into the bloodstream, cancer patients also exhibit increased levels of DNA from immune cells. Contrary to previous assumptions that this immune DNA would dilute tumor signals, the study revealed that both tumor and immune cell DNA levels rise in tandem, enhancing the detection of cancer-related signals.
CancerSpot utilizes advanced DNA sequencing combined with artificial intelligence to identify specific methylation patterns that differentiate cancer cells from normal cells. The study demonstrated a remarkably low false positive rate of just 1.4%, while successfully detecting 72% of cancer cases. This validation by an international panel of experts underscores the reliability of the CancerSpot methodology and its potential for early cancer detection.
Dr. Ramesh Hariharan, CEO of Strand Life Sciences, emphasized the importance of balancing sensitivity and specificity in early cancer detection. He noted that the publication in PNAS validates the scientific rigor of their work and marks a pivotal step in making reliable early detection accessible in India. Dr. Tarang Gianchandani, CEO of Sir H.N. Reliance Foundation Hospital, highlighted the transformative potential of early detection in cancer care and expressed confidence in the collaboration with Strand to advance precision diagnostics.
Looking ahead, Dr. Sewanti Limaye, Director of Medical & Precision Oncology at Sir H.N. Reliance Foundation Hospital and a co-author of the study, stated that the findings challenge existing assumptions in liquid biopsy science. The immediate goal is to develop independently validated screening strategies that leverage these insights to improve early diagnosis and patient outcomes, paving the way for a new era in cancer detection.




